Pharmacologic inhibition of both the immune-checkpoint molecule PD-L1 and vascular endothelial growth factor improves survival among persons with hepatocellular carcinoma. The success of this combination therapy may depend on the context in which hepatocellular carcinoma arises.
No takes yet. Share an insight, caveat, or question.
Kelley et al. (2021) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: